Ironwood Pharmaceuticals, Inc. updated financial guidance for the full year 2021. For the year, company expects total revenue at the High end of $390 million to $410 million against previous guidance of $390 million to $410 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.88 USD | +0.77% | -2.23% | -31.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.12% | 1.25B | |
+1.77% | 42.86B | |
+43.29% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Updates Financial Guidance for the Full Year 2021